Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

Kite Pharma has appointed two former Amgen directors to senior positions in its research team.

Dr William Go joins as senior director, clinical development, and Jeff Aycock joins as senior director, clinical operations. 

Dr Go was most recently US medical lead for Amgen's cancer treatments Vectibix (panitumumab) and medical director in the company's global development business. Aycock, meanwhile, was most recently director, oncology study management and US regional lead at Amgen, overseeing five oncology programmes.

The two will now add their expertise in cancer to Kite as it plans to advance its immunotherapy plans in oncology.

They are the fourth and fifth senior figures to make their way from Amgen to Kite this year, following the appointments of VP, clinical development, Dr Jeffrey Wiezorek in May and of chief medical officer Dr David Chang earlier this month to replace Dr Keith Nolop who spent just one year in the role.

Outside R&D, Kite also added Dr Rizwana Sproule from Amgen as head VP, regulatory affairs in January.

24th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics